China Pharma Financials
This page shows China Pharma (CPHI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
China Pharma has an operating margin of -101.3%, meaning the company retains $-101 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -39.3% the prior year.
China Pharma's revenue declined 35.4% year-over-year, from $7.0M to $4.5M. This contraction results in a growth score of 0/100.
China Pharma carries a low D/E ratio of 0.92, meaning only $0.92 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 77/100, indicating a strong balance sheet with room for future borrowing.
China Pharma's current ratio of 0.65 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 6/100, which could limit financial flexibility.
While China Pharma generated -$466K in operating cash flow, capex of $38K consumed most of it, leaving -$505K in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
China Pharma passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, China Pharma generates $0.10 in operating cash flow (-$466K OCF vs -$4.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
China Pharma earns $-167.8 in operating income for every $1 of interest expense (-$4.6M vs $27K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
China Pharma generated $4.5M in revenue in fiscal year 2024. This represents a decrease of 35.4% from the prior year.
China Pharma's EBITDA was -$2.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 107617.7% from the prior year.
China Pharma generated -$505K in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 29.0% from the prior year.
China Pharma reported -$4.7M in net income in fiscal year 2024. This represents a decrease of 53.8% from the prior year.
China Pharma earned $-0.27 per diluted share (EPS) in fiscal year 2024. This represents an increase of 70.3% from the prior year.
China Pharma held $627K in cash against $0 in long-term debt as of fiscal year 2024.
China Pharma had 3M shares outstanding in fiscal year 2024. This represents a decrease of 69.3% from the prior year.
China Pharma's gross margin was -43.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 39.8 percentage points from the prior year.
China Pharma's operating margin was -101.3% in fiscal year 2024, reflecting core business profitability. This is down 62.1 percentage points from the prior year.
China Pharma's net profit margin was -104.6% in fiscal year 2024, showing the share of revenue converted to profit. This is down 60.7 percentage points from the prior year.
China Pharma invested $284K in research and development in fiscal year 2024. This represents an increase of 18.3% from the prior year.
China Pharma invested $38K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 233.5% from the prior year.
CPHI Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $756K-26.3% | $1.0M-9.7% | $1.1M+0.2% | $1.1M+22.6% | $925K-32.5% | $1.4M-36.3% | $2.1M+19.2% | $1.8M |
| Cost of Revenue | $816K-26.7% | $1.1M-12.5% | $1.3M-1.7% | $1.3M-33.3% | $1.9M+16.9% | $1.7M-25.5% | $2.2M+9.4% | $2.0M |
| Gross Profit | -$60K+31.4% | -$87K+36.1% | -$136K+15.3% | -$161K+84.2% | -$1.0M-250.1% | -$290K-266.4% | -$79K+66.1% | -$233K |
| R&D Expenses | $40K+92.4% | $21K-29.2% | $30K+5309.0% | $547-99.7% | $164K+422.5% | $31K-78.7% | $148K+222.4% | $46K |
| SG&A Expenses | $425K-3.6% | $441K-13.1% | $507K-41.0% | $859K+835.4% | $92K-81.2% | $488K-29.2% | $690K+180.1% | $246K |
| Operating Income | -$628K+3.7% | -$652K+14.0% | -$759K+36.6% | -$1.2M+14.0% | -$1.4M-51.9% | -$916K+22.7% | -$1.2M-66.0% | -$714K |
| Interest Expense | $7K+0.3% | $7K-0.1% | $7K-0.2% | $7K-0.7% | $7K-0.1% | $7K+103.5% | -$193K-2887.1% | $7K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$651K-23.3% | -$528K+32.7% | -$786K+35.8% | -$1.2M+14.9% | -$1.4M-50.4% | -$956K+22.4% | -$1.2M-58.5% | -$778K |
| EPS (Diluted) | $-0.17-6.3% | $-0.16 | $-0.24 | $1.99 | $-0.89-23.6% | $-0.72-242.9% | $-0.21 | $-0.29 |
CPHI Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $15.8M+14.8% | $13.8M-3.2% | $14.2M-4.5% | $14.9M+4.4% | $14.3M | N/A | $16.5M+7.3% | $15.4M |
| Current Assets | $2.3M-13.8% | $2.7M-5.3% | $2.9M-12.8% | $3.3M-17.7% | $4.0M | N/A | $6.0M+3.3% | $5.8M |
| Cash & Equivalents | $268K-55.4% | $600K+50.0% | $400K-36.2% | $627K-15.2% | $739K-11.9% | $839K-41.1% | $1.4M+3.9% | $1.4M |
| Inventory | $1.6M-1.7% | $1.7M-15.2% | $2.0M-12.7% | $2.3M-19.6% | $2.8M | N/A | $3.7M-0.9% | $3.8M |
| Accounts Receivable | $225K-16.4% | $269K-18.3% | $329K+41.7% | $232K-8.9% | $255K | N/A | $504K+37.0% | $368K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $7.5M+2.5% | $7.3M+0.8% | $7.2M+1.5% | $7.1M+4.2% | $6.9M | N/A | $9.0M-2.5% | $9.2M |
| Current Liabilities | $6.6M+26.1% | $5.3M+2.5% | $5.1M+2.1% | $5.0M+6.5% | $4.7M | N/A | $6.8M-3.4% | $7.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $8.3M+28.7% | $6.5M-7.3% | $7.0M-10.0% | $7.7M+4.6% | $7.4M-10.7% | $8.3M+11.2% | $7.5M+22.0% | $6.1M |
| Retained Earnings | -$46.0M-1.4% | -$45.3M-1.2% | -$44.8M-1.8% | -$44.0M-5.6% | -$41.7M | N/A | -$39.3M-3.2% | -$38.1M |
CPHI Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$237K-181.4% | $291K+603.4% | -$58K-124.2% | $238K+427.9% | -$73K+87.6% | -$585K-2521.3% | -$22K-102.2% | $1.0M |
| Capital Expenditures | $611+1040.0% | -$65-100.1% | $58K+198.4% | $20K | N/A | N/A | N/A | N/A |
| Free Cash Flow | -$238K-181.6% | $291K+350.6% | -$116K-153.1% | $219K | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$41K-309.2% | -$10K+87.7% | -$81K+70.3% | -$273K | N/A | N/A | -$5K+93.3% | -$67K |
| Financing Cash Flow | -$122K-318.7% | -$29K+58.3% | -$70K-1129.6% | $7K-0.7% | $7K-0.1% | $7K-77.4% | $30K+106.4% | -$476K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CPHI Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -7.9%+0.6pp | -8.5%+3.5pp | -12.0%+2.2pp | -14.2%+95.6pp | -109.8%-88.6pp | -21.2%-17.5pp | -3.7%+9.3pp | -12.9% |
| Operating Margin | -83.1%-19.5pp | -63.6%+3.2pp | -66.8%+38.7pp | -105.5%+45.0pp | -150.4%-83.6pp | -66.9%-11.8pp | -55.1%-15.5pp | -39.6% |
| Net Margin | -86.2%-34.6pp | -51.5%+17.6pp | -69.1%+38.9pp | -108.0%+47.5pp | -155.5%-85.7pp | -69.8%-12.5pp | -57.3%-14.2pp | -43.1% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -4.1%-0.3pp | -3.8%+1.7pp | -5.5%+2.7pp | -8.2%+1.9pp | -10.1% | N/A | -7.5%-2.4pp | -5.1% |
| Current Ratio | 0.35-0.2 | 0.51-0.0 | 0.56-0.1 | 0.65-0.2 | 0.84 | N/A | 0.88+0.1 | 0.82 |
| Debt-to-Equity | 0.90-0.2 | 1.13+0.1 | 1.04+0.1 | 0.920.0 | 0.93 | N/A | 1.21-0.3 | 1.51 |
| FCF Margin | -31.4%-59.8pp | 28.4%+38.6pp | -10.2%-29.5pp | 19.3% | N/A | N/A | N/A | N/A |
Note: The current ratio is below 1.0 (0.65), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is China Pharma's annual revenue?
China Pharma (CPHI) reported $4.5M in total revenue for fiscal year 2024. This represents a -35.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is China Pharma's revenue growing?
China Pharma (CPHI) revenue declined by 35.4% year-over-year, from $7.0M to $4.5M in fiscal year 2024.
Is China Pharma profitable?
No, China Pharma (CPHI) reported a net income of -$4.7M in fiscal year 2024, with a net profit margin of -104.6%.
What is China Pharma's earnings per share (EPS)?
China Pharma (CPHI) reported diluted earnings per share of $-0.27 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is China Pharma's EBITDA?
China Pharma (CPHI) had EBITDA of -$2.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is China Pharma's gross margin?
China Pharma (CPHI) had a gross margin of -43.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is China Pharma's operating margin?
China Pharma (CPHI) had an operating margin of -101.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is China Pharma's net profit margin?
China Pharma (CPHI) had a net profit margin of -104.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is China Pharma's free cash flow?
China Pharma (CPHI) generated -$505K in free cash flow during fiscal year 2024. This represents a 29.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is China Pharma's operating cash flow?
China Pharma (CPHI) generated -$466K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are China Pharma's total assets?
China Pharma (CPHI) had $14.9M in total assets as of fiscal year 2024, including both current and long-term assets.
What are China Pharma's capital expenditures?
China Pharma (CPHI) invested $38K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does China Pharma spend on research and development?
China Pharma (CPHI) invested $284K in research and development during fiscal year 2024.
How many shares does China Pharma have outstanding?
China Pharma (CPHI) had 3M shares outstanding as of fiscal year 2024.
What is China Pharma's current ratio?
China Pharma (CPHI) had a current ratio of 0.65 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is China Pharma's debt-to-equity ratio?
China Pharma (CPHI) had a debt-to-equity ratio of 0.92 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is China Pharma's return on assets (ROA)?
China Pharma (CPHI) had a return on assets of -31.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is China Pharma's cash runway?
Based on fiscal year 2024 data, China Pharma (CPHI) had $627K in cash against an annual operating cash burn of $466K. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is China Pharma's Piotroski F-Score?
China Pharma (CPHI) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are China Pharma's earnings high quality?
China Pharma (CPHI) has an earnings quality ratio of 0.10x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can China Pharma cover its interest payments?
China Pharma (CPHI) has an interest coverage ratio of -167.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is China Pharma?
China Pharma (CPHI) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.